Mesterolone (International)
Scheme
Rec.INN
ATC (Anatomical Therapeutic Chemical Classification)
G03BB01
CAS registry number (Chemical Abstracts Service)
0001424-00-6
Chemical Formula
C20-H32-O2
Molecular Weight
304
Therapeutic Categories
Anabolic agent
Androgen
Chemical Name
Androstan-3-one, 17-hydroxy-1-metyl-, (1α,5α,17β)-
Foreign Names
- Mesterolonum (Latin)
- Mesterolon (German)
- Mestérolone (French)
- Mesterolona (Spanish)
Generic Names
- Mesterolone (OS: BAN, DCIT, USAN)
- Mestérolone (OS: DCF)
- SH 60723 (IS)
- SH 723 (Schering) (IS)
- Mesterolon (PH: Ph. Eur. 9)
- Mesterolone (PH: BP 2018, Ph. Eur. 9)
- Mestérolone (PH: Ph. Eur. 9)
- Mesterolonum (PH: Ph. Eur. 9)
Brand Names
- Androlon
Meprofarm, Indonesia - Cidoviron
Cid, Egypt - Hormo
Delta Pharma, Egypt - Infelon
Caprifarmindo, Indonesia - Mesviron
Samarth Pharma, Thailand - Provimest
hi pharm, Egypt - Proviron
Bayer, Belgium; Bayer, Brazil; Bayer, Ecuador; Bayer, Egypt; Bayer, Greece; Bayer, Italy; Bayer, Oman; Bayer, Philippines; Bayer, Poland; Bayer, Portugal; Bayer, Slovakia; Bayer, Turkey; Bayer, Uruguay; Bayer Australia, Australia; Bayer de México, Mexico; Bayer Healthcare, Indonesia; Bayer Hispania, Spain; Bayer Israel Ltd, Israel; Bayer Pharmaceuticals, Kuwait; Bayer Schering, South Africa; BSP Bayer Schering Pharma, Paraguay; Schering, Lebanon - Pro-Viron
Bayer, United Kingdom; Bayer, Malta - Proviron 25mg
Bayer, Hungary; Bayer, Luxembourg - Provironum
Bayer South East Asia, Vietnam; Bayer Health Care, Malaysia; Bayer HealthCare, Singapore; Bayer Thai Co Ltd, Thailand; Zydus, India - Restore
Micro B & B, India
Glossary
| Term | Definition |
|---|---|
| BAN | British Approved Name |
| DCF | Dénomination Commune Française |
| DCIT | Denominazione Comune Italiana |
| IS | Inofficial Synonym |
| OS | Official Synonym |
| PH | Pharmacopoeia Name |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
Further information on drug naming conventions: International Nonproprietary Names.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.